Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
Healthcare
$0.90 +3.01%
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
52W Low $1.07High $6.18
Volume 1.45M
Average 2.13M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$35.27M
FY 2025 · Annual
Net Income
-$33.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
| Selling, General & Admin | 11.28M | 15.37M | 13.34M | 11.89M | 9.6M |
| Operating Expenses | 56.22M | 62.68M | 42.79M | 60.12M | 35.27M |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| EBITDA | (55.77M) | (60.07M) | (35.21M) | (53.68M) | (31.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (56.22M) | (62.68M) | (42.79M) | (60.12M) | (35.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 185.36K | 2.35M | 7.32M | 6.19M | 3.32M |
| Interest Expense | 1.74M | 1.69M | 2.07M | 1.93M | 1.91M |
| Other Income / Expenses | (1.56M) | 655.35K | 5.25M | 4.27M | 1.42M |
| Income Before Tax | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| EPS (Diluted) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| 54.04M | 58.41M | 58.94M | 59.48M | 60.06M | |
| 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
ALDX Earnings Waterfall · TTM
NASDAQ:ALDX · Revenue to Net Income
Key Ratios
EPS$-0.46
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$27.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.46, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Aug 12, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 | |
| 8-K | Current report | Jul 30, 2026 | |
| SC 13G/A | SC 13G/A filing | Jul 27, 2026 | |
| 8-K | Current report | Jul 15, 2026 |
How much revenue does ALDX generate?
Aldeyra Therapeutics, Inc. (ALDX) reported $0.00 of revenue in fiscal 2025.
Is ALDX profitable?
Aldeyra Therapeutics, Inc. (ALDX) reported -$33.85M of net income.
Continue the stock analysis
Jump to another research area for this company.